Email Us
Call Us
AUSTIN, Texas – December 18, 2012 – Altogen delivery technology is cited across a body of infectious disease and innate immunity research, including studies published in Nature and PLoS Pathogens examining how the innate immune system distinguishes viral RNA from host RNA. Any nucleic acid therapeutic — siRNA, mRNA, antisense oligonucleotide, plasmid DNA — risks triggering innate immune recognition, and an unintended interferon response can be mistaken for on-target pharmacology or can shut a program down late in development. Understanding sequence-dependent immune activation is not a peripheral concern in oligonucleotide development; it is a core safety question. Altogen Labs supports sponsors on both sides of that question. The company performs in vivo delivery studies with chemically modified oligonucleotides designed to minimize immune activation, alongside immune response and biomarker analysis, cytokine profiling by ELISA, gene expression analysis by RT-PCR, and protein quantification by automated capillary Western.
Beyond oncology, the company conducts preclinical work in infectious disease, immunology, inflammation, and vaccine evaluation. Immuno-oncology programs are served by humanized and immunodeficient rodent models, including animals engrafted with peripheral blood mononuclear cells (PBMC), CD34+ hematopoietic stem cells, and induced pluripotent stem cells (iPSC), together with syngeneic murine models including CT26, MC38, 4T1, B16, LL2, EL4, A20, Renca, S180, H22, and Hepa 1-6. All studies are conducted under GLP-compliant, IACUC-regulated conditions with complete documentation delivered to the sponsor.
About Altogen Labs Altogen Labs is a professional, experienced, and highly reputable GLP-compliant contract research organization providing preclinical research and biology CRO services worldwide, with a large collection of validated xenograft models and extensive experience in efficacy xenograft and safety toxicology studies.
Contact Information: Altogen Labs | 11200 Menchaca Rd, Bldg 2, Suite 203 | Austin, TX 78748 USA Tel: 512-433-6177 | Email: info@altogenlabs.com | Web: altogenlabs.com
Source citations: Saito T, et al., Nature, 2008;454(7203):523; and Schnell G, et al., “Uridine composition of the poly-U/UC tract of HCV RNA defines non-self recognition by RIG-I,” PLoS Pathogens, 2012;8(8)